News Releases

Date Title and Summary Additional Formats
Jul 01, 2021 Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants
Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24 hours of infectious SARS-CoV-2 challenge with absence of subgenomic RNA at Day 3 and Day 5 post-challenge Varenicline inhibits cellular entry and replication of
Jun 29, 2021 Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray
PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray following the announcement that an unrelated manufacturer of varenicline oral tablets has suspended
Jun 21, 2021 Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced that the Company will
Jun 21, 2021 Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy
PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ophthalmic diseases, today announced enrollment of the first
Jun 10, 2021 Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technology Oyster Point Pharma plans to discuss the potential for bacteriophage in the treatment of ophthalmic diseases at the upcoming Oyster Point Pharma Analyst
Jun 03, 2021 Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases
Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK) Preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an
May 06, 2021 Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 Continued Organizational Advancement
May 01, 2021 Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at the Association for Research in Vision and Ophthalmology 2021 Virtual Annual Meeting
PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data
Apr 30, 2021 Oyster Point Pharma to Report First Quarter 2021 Financial Results on May 6, 2021
Conference Call and Webcast Scheduled for May 6, 2021, 4:30 p.m. Eastern Time PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class
Apr 05, 2021 Oyster Point Pharma Announces New Appointment to Board of Directors
George Eliades joins the Board of Directors PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular
Displaying 1 - 10 of 14